



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", #12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Date: 19th November, 2021

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, 05th Floor,
Plot No: C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400051

Sub: Intimation U/R 30 of the SEBI (LODR) Regulations 2015- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited, Unit III R&D facility clears US FDA Remote Record Review with no observations.

Dear Sir / Madam,

This is to inform you that US FDA has concluded Remote Record Review of Shilpa Medicare Limited ('SML' or 'the Company'), Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th Nov 2021.

Shilpa Medicare Limited, Unit III, R&D facility is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.

This is for your information and doing the needful.

For Shilpa Medicare Limited,


V V Krishna Chaitanya
Company Secretary &
Compliance Officer

